ANVS (Annovis Bio) GF Value : $0.00 (As of Mar. 25, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Annovis Bio GF Value?

As of today (2025-03-25), Annovis Bio's share price is $1.85. Annovis Bio's GF Value is $0.00. Therefore, Annovis Bio's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes Annovis Bio is Not Valued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

Annovis Bio (NYSE:ANVS) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Annovis Bio's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	1.85	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annovis Bio GF Value Related Terms

Thank you for viewing the detailed overview of Annovis Bio's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Annovis Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (NYSE:ANVS) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

07X:Germany

Address

101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355

Website

https://www.annovisbio.com

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Executives

Henry Iii Hagopian	officer: Chief Financial Officer	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Mark K. White	director	227 7TH AVENUE NE, ST. PETERSBURG FL 33701
Claudine Bruck	director	4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552
Maria-luisa Maccecchini	director, officer: President and CEO	1223 FOXGLOVE LANE, WEST CHESTER PA 19380
Reid Mccarthy	director	1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jeffrey Brian Mcgroarty	officer: Chief Financial Officer	360 HILLTOP RD, PAOLI PA 19301
Whelan, Jr. Robert M.	director	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Michael B Hoffman	director	1 GREENWICH OFFICE PARK, GREENWICH CT 06831